NCT00491296UnknownNot Applicable
Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With Hyperthermia
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Locations
- 2
Study Overview
Brief Summary
PURPOSE: We determined whether Synergo therapy- intravesical chemotherapy instillation combined with hyperthermia instillation is associated with elevated prostate specific antigen (PSA). MATERIALS AND METHODS: We will treat 25 consecutive patients with bladder cancer with a 6-week course of Synergo therapy, followed by cystoscopy at 6 weeks. Blood samples for PSA determination will obtain before each synergo therapy application and at cystoscopy with each patient also serving as a control.
Evaluating changes in PSA level in patients undergoing treatment with Synergo delivered local hyperthermia combined with intravesical instillation of Mitomycin C for adjuvant treatment or pt. with recurrent tu of bladder post TURT with BCGtreatment.
Study Design
- Study Type
- Observational
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 30 Years to 90 Years (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Recurrent transitional cell carcinoma of urinary bladder post endoscopic resection
- •PSA Prior synergo therapy application<10
- •Normal rectal examination
- •Patients willing to sign informed consent according
Exclusion Criteria
- •History of prostate cancer
- •Previous history of TCC stage T2 or higher
- •Invasive tu of bladder
- •Prior pelvic radiotherapy or systemic chemotherapy
- •Active prostatitis
- •Active tuberculosis
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 2
Combination Immunotherapy in Biochemically Recurrent Prostate CancerProstate CancerNCT03315871National Cancer Institute (NCI)40
Completed
Not Applicable
Effects of Alpha Blockers on Prostate-specific Antigen (PSA) Change in Men With Lower Urinary Tract Symptoms (LUTS)Benign Prostatic HyperplasiaProstate CancerNCT01250483Seoul National University Hospital174
Completed
Not Applicable
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive TreatmentProstate CancerNCT00694551H. Lee Moffitt Cancer Center and Research Institute29
Completed
Phase 4
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)Prostatic NeoplasmsNCT04108208Janssen Research & Development, LLC75
Recruiting
Phase 3
Effect of new combined medication Young Prostate on clinical symptoms in patients with benign prostate hypertrophy and overactive bladderBenign prostate hypertrophy.Benign neoplasm of prostateD29.1IRCT20120215009014N386Hamedan University of Medical Sciences64